<DOC>
	<DOCNO>NCT00003802</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness pyrazoloacridine treat patient metastatic skin eye melanoma .</brief_summary>
	<brief_title>Pyrazoloacridine Treating Patients With Metastatic Skin Eye Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess antitumor activity pyrazoloacridine ( PZA ) chemotherapy naive patient metastatic cutaneous ocular melanoma . - Determine toxic effect PZA patient population . - Determine pharmacokinetic profile PZA patient . OUTLINE : Patients stratify cutaneous ocular melanoma treatment group . Patients receive pyrazoloacridine IV 3 hour day 1 . Treatment continue every 21 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 28-70 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>NSC 366140</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic cutaneous ocular melanoma chemotherapy naive Bidimensionally measurable disease No pleural effusion ascites No untreated CNS metastasis Stable brain metastasis CT MRI scan At least 4 week since prior steroid therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 4,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN ( unless due hepatic metastasis ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No active infection No known hypersensitivity E.coli derive proteins No serious medical problem No 1 primary malignancy within past 5 year , : Nonmelanomatous skin cancer Carcinoma situ cervix No history spinal cord compression PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow ( e.g. , interleukin2 , interferon alfa , vaccine therapy ) Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : Prior radiotherapy primary ocular melanoma , brain metastasis , metastatic site encompass less 25 % bone marrow allow No prior radiotherapy Surgery : At least 2 week since prior surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>